SCHEDULE 13G/A: Rock Springs Capital Amends Stake in Aclaris Therapeutics, Disclosing 4.7% Beneficial Ownership
Beneficial Ownership Report
Rock Springs Capital Management LP and its affiliated entities have filed an amendment to their Schedule 13G, reporting a 4.7% beneficial ownership stake in Aclaris Therapeutics, Inc.
Summary
- Rock Springs Capital Management LP, Rock Springs Capital LLC, Mark Bussard, and Kris Jenner have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Aclaris Therapeutics, Inc.
- As of March 31, 2025, the reporting persons collectively beneficially own 5,046,309 shares of Aclaris Therapeutics, Inc. Common Stock.
- This aggregate amount represents 4.7% of Aclaris Therapeutics, Inc.'s outstanding Common Stock.
- The percentage is calculated based on 107,918,821 shares outstanding, as reported in Aclaris Therapeutics, Inc.'s 10-K filing on February 27, 2025.
- The reporting persons, including Rock Springs Capital Management LP (investment manager), Rock Springs Capital LLC (general partner of RSCM), and individuals Mark Bussard and Kris Jenner (who each own 50% of the management company), hold shared voting and dispositive power over all 5,046,309 shares.
- The shares are held directly by Rock Springs Capital Master Fund LP and Four Pines Master Fund LP, with indirect beneficial ownership attributed to the reporting persons.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of institutional ownership, common in the financial industry, indicating a significant but non-controlling stake by an investment firm in a publicly traded biotechnology company. It reflects an investment position rather than operational or strategic insights into Aclaris Therapeutics, Inc. or the broader pharmaceutical/biotechnology sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 02/27/2025 | Date of Issuer's 10-K filing, which reported 107,918,821 shares outstanding used for percentage calculation. |
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership snapshot date). |
| 05/15/2025 | Date of signing for Rock Springs Capital Management LP, Rock Springs Capital LLC, Rock Springs Capital Master Fund LP, Mark Bussard, and Kris Jenner. |
Keywords
Aclaris Therapeutics, Rock Springs Capital, Beneficial Ownership, Schedule 13G, SEC Filing, Common Stock, Institutional Investor, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.